Wuhan Hvsen Biotechnology Co Ltd (300871) — Cash Flow-to-Debt Ratio
Wuhan Hvsen Biotechnology Co Ltd (300871) has a Cash Flow-to-Debt Ratio of 0.07x as of September 2025, meaning its operating cash flow of CN¥59.06 Million could theoretically repay 0% of its total liabilities (CN¥839.94 Million) in one year. See Wuhan Hvsen Biotechnology Co Ltd (300871) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Wuhan Hvsen Biotechnology Co Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Wuhan Hvsen Biotechnology Co Ltd across 10 annual periods. For the full cash flow conversion analysis, see Wuhan Hvsen Biotechnology Co Ltd cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Wuhan Hvsen Biotechnology Co Ltd (2016–2025)
Year-by-year debt coverage analysis for Wuhan Hvsen Biotechnology Co Ltd. Check Wuhan Hvsen Biotechnology Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.29x | CN¥238.45 Million | CN¥822.17 Million | ▲ +932.3% |
| 2024 | 0.03x | CN¥43.53 Million | CN¥1.55 Billion | ▼ -55.7% |
| 2023 | 0.06x | CN¥92.92 Million | CN¥1.47 Billion | ▼ -5.1% |
| 2022 | 0.07x | CN¥96.68 Million | CN¥1.45 Billion | ▼ -51.8% |
| 2021 | 0.14x | CN¥155.72 Million | CN¥1.12 Billion | ▲ +7.0% |
| 2020 | 0.13x | CN¥48.35 Million | CN¥373.08 Million | ▼ -66.5% |
| 2019 | 0.39x | CN¥105.24 Million | CN¥271.80 Million | ▲ +160.8% |
| 2018 | 0.15x | CN¥21.10 Million | CN¥142.08 Million | ▼ -77.7% |
| 2017 | 0.67x | CN¥80.56 Million | CN¥121.06 Million | ▲ +12.2% |
| 2016 | 0.59x | CN¥60.00 Million | CN¥101.16 Million | — |